Moderna, Inc. (MRNA) vs Solventum Corporation (SOLV)

SOLV leads on 7 of 8 compared metrics.

A side-by-side comparison of Moderna, Inc. and Solventum Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 14, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).

Total return — MRNA vs SOLV

growth of $100 · last 2y
MRNA -53.5%SOLV -1.4%SOLV compounded faster
50100150Start $10020252026$46$99
MRNA SOLV

MRNA vs SOLV: by the numbers

  • MRNA is the larger company ($19.80B vs $13.66B market cap).
  • SOLV is profitable (17.33% net margin) while MRNA runs a net loss (-143.55%).
  • SOLV grew revenue faster over the past five years (2.72% vs -2.60% CAGR).

Which is better, MRNA or SOLV?

Metric tally: MRNA 1 · SOLV 7

It depends on what you're optimizing for:

GrowthSOLV(faster 5Y revenue CAGR)
QualitySOLV(higher ROIC)

Valuation

MetricMRNASOLV
P/E ratio9.65
Forward P/E11.17
P/S ratio8.861.68
P/B ratio2.662.79
PEG ratio0.04
EV / EBITDA6.67

Profitability

MetricMRNASOLV
Gross margin-13.89%53.67%
Operating margin-153.35%25.54%
Net margin-143.55%17.33%
ROE-43.12%28.82%
ROIC-29.70%17.76%

Growth (annualized)

MetricMRNASOLV
Revenue CAGR (5Y)-2.60%2.72%
EPS CAGR (5Y)6.26%
FCF CAGR (5Y)126.92%
Total return CAGR (5Y)-25.58%

Frequently asked

Which is better, MRNA or SOLV?
It depends on your goal. growth: SOLV (faster 5Y revenue CAGR); quality: SOLV (higher ROIC). Across all compared metrics, SOLV leads 7 to 1.
Which has grown faster, MRNA or SOLV?
Over the past five years, SOLV grew revenue faster — MRNA at a -2.60% CAGR versus SOLV at 2.72%.
Is MRNA or SOLV more profitable?
SOLV runs the higher net margin — MRNA at -143.55% versus SOLV at 17.33%.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 14, 2026.